User 199522

Potential for Huge Profits Awaits Big Pharma Companies

the last comment is partly correct and partly a fuss. Cisplatin has been generic for many years and there is considerable competition leading to pricing much much below what the post indicated. Additionally, Michigan State University received well in excess of 250 million dollars in royalties for cothe cisplatin and its follow up carboplatin. The innovator at MSU was able to build a institute on his funds. Thus, the innovator was well rewarded while BMS put in hundreds of millions of dollars in the actual pharmaceutical development of the drug and label expansion. Not all drugs arise from federally funded research. Between what is explored in university laboratories and what is developed through targeted research at company labs, drugs arise.